tirzepatide surpass-5 Significantly Reduced A1C and Body Weight in People with Type 2 Diabetes in Two Phase 3 Trials from Lilly's SURPASS Program-CliniExpert Obesity drug seen as effective

Weight regain after stopping tirzepatide is common and can occur rapidly in some patients

We currently intend to use the net proceeds from this offering and the concurrent private placement, together with our existing cash and cash equivalents as follows: Based on our current operating plan, we believe that our existing cash and cash equivalents, together with the net proceeds from this offering, will be sufficient for us to fund our operations into 2029

How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test may help provide context for your individual appetite-regulation profile by analyzing predispositions in GIPR, FTO, and MC4R pathways

Semaglutide shelf life after reconstitution or first use depends on the formulation